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Summary
 › The consumption of medicines is increasing. Most of 
the pharmaceutical substances taken by humans and 
animals are excreted and can be found in many water 
bodies and partly even in groundwater.
 › Currently, based on existing studies, an acute or chronic 
health risk from pharmaceutical substances in drinking 
water can be excluded. However, there are strong indi-
cations that pharmaceutical residues in combination 
with other micropollutants affect aquatic communities. 
Overall, there are still gaps of knowledge with regard to 
the occurrence and effects of pharmaceutical residues in 
the environment.
 › With a series of measures, it is possible to reduce the 
discharge of pharmaceutical substances into the aquatic 
environment  –  without compromising health protec-
tion. Here, a combination of different measures seems 
to make sense. In this context, there is an intense debate 
focusing on the upgrading of large sewage treatment 
plants with a fourth treatment stage.
 › It is necessary to consider which tangible measures 
should be taken within the framework of a comprehen-
sive micropollutant strategy that is to be pursued.
What is involved
Most medicines administered to humans or animals do not 
remain in the body, but are excreted unchanged or in the 
form of metabolites. Ultimately, they reach rivers and lakes 
via various routes and, in some cases, even end up in ground-
water. The question arises as to whether these micropollu-
tants pose a danger to humans and the environment and to 
what extent there is a need for action.
With regard to the extent and trends of micropollutants 
in water bodies, groundwater and drinking water, the data 
situation is unsatisfactory, as there is no comprehensive 
and systematic monitoring of micropollutants in ground-
waters and surface waters in Germany to date. However, 
sampling and estimates indicate an increase in micropol-
lutants. These observations are confirmed by the growing 
total consumption of human medicines. Between 2002 and 
2012, consumption increased by 30 % to 8,120 t per year. 
For veterinary medicines, it is not possible to accurately 
estimate the total quantities consumed, as only antibiotics 
and some other selected active pharmaceutical ingredients 
are subject to official registration. After all, the consump-
tion of antibiotics in the veterinary sector has halved from 
1,706 t (2011) to 805 t (2015), partly due to legal measures. 
Since the degradation processes in the environment take a 
lot of time and the consumption of human and veterinary 
medicines will probably continue to rise, the occurrence 
and concentration of pharmaceutical substances and their 
degradation products in the environment will presumably 
continue to increase as well.
Residues of human medicines in concentrations of up to 
10 µg/l, sometimes even significantly higher, were found in 
water bodies and particularly in effluents from sewage treat-
ment plants. Residues of veterinary medicines, how ever, 
could only be detected sporadically in waters. In the raw 
water of waterworks, the concentration of pharmaceutical 
residues is generally very low or even below the limit of de-
tection. However, in some regions – such as the Hessian Ried 
and parts of Berlin – limit values were exceeded.
Pharmaceutical substances are typically characterised by the 
fact that they are physiologically effective even in low con-
centrations. In this context, however, there are currently no 
indications that the consumption of drinking water is harm-
ful to human health. Nor are the pharmaceutical residues in 
surface waters directly dangerous to humans in the concen- 
trations currently measured. Though, it is unclear whether 
residues of antibiotics in the aquatic environment contri-
bute to the development and spread of antibiotic resistance. 
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of a large number of different micropollutants – not only 
pharmaceutical substances. Thus, the fourth treatment stage 
is an exception to the rule that measures at the source are 
superior to so-called end-of-pipe technologies. Conversely, 
however, this does not mean that a limitation to the use of 
the fourth treatment stage is sufficient. This is due to the fact 
that it is impossible to eliminate pollutants completely and 
unwanted secondary substances can be produced. Moreover, 
the entry paths for veterinary medicines are not recorded.
Residues of veterinary medicines typically take a different 
route than residues of human medicines. They are spread 
on meadows and fields with liquid manure and dung from 
stables. In case of pasture grazing, they also reach meadows. 
From there, they get into the soil and seep into groundwater, 
Findings of antibiotic-resistant germs in bathing waters and 
the underflows of sewage treatment plants have fuelled such 
fears. In this context, there are still large gaps of knowledge 
and a substantial need for research.
In contrast to humans, fish 
and other aqua tic organisms 
are directly exposed to phar-
maceutical residues in waters. 
Laboratory tests and first field 
observations show that some 
residues pollute the environ-
ment. The most problematic 
substances are those that have 
an effect on the endocrine 
system of organisms.
In view of the more frequent 
occurrence and the increasing 
concentration of pharmaceu-
tical residues in water bodies 
and groundwater as well as 
with regard to the indications 
of negative environmental im-
pacts and – at the same time – 
large gaps of knowledge, the 
question arises from a precau-
tionary perspective as to which 
measures should be taken.
Measures at the source or at the end of pipe?
Residues from human medicines are discharged with the 
waste water into the sewage system. The sewage channels 
act like a kind of funnel and bundle the waste water streams. 
With the currently used purification technologies, pharma-
ceutical residues are only partially retained in sewage treat-
ment plants. In municipal sewage treatment plants, however, 
an elaborate fourth treatment stage can eliminate about 80 % 
Antibiotic resistance
 › Antibiotics are medicines against bacterial infections. However, bacteria can become resistant to antibiotics. Thus, antibio-
tics lose their effectiveness. Antibiotic resistance is a serious threat to public health. It is estimated that about 700,000 people 
worldwide die each year from an infectious disease, because germs are resistant to the antibiotics available.
 › Bacteria multiply quickly and, in doing so, change their genetic material. If an antibiotic is insufficiently dosed so that it does 
not completely prevent the bacteria from multiplying, it exerts a selection pressure on the bacteria, which favours the devel-
opment of resistant germs. Antibiotic resistance can therefore develop where antibiotics occur in increased concentrations, 
e. g. in hospitals or animal stables.
 › Although water bodies in Germany are certainly not the main source of antibiotic resistance, the detection of multi-resistant 
germs in streams, rivers and bathing lakes in Lower Saxony in February 2018 was surprising and raised concern. The concen-
trations of antibiotics in German waters are actually too low to exert a significant selection pressure on bacteria. This is why 
it currently remains unclear where the resistances have developed and how they have spread. There is a considerable need 
for research with regard to this issue.
Fig. 1 Sewage treatment plant with fourth treatment stage
Image: BR-Studio Franken/Michael Reiner
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would be imaginable to reduce the discharge of residues from 
pharmaceutical production into waters e. g. by changing pro-
duction processes or better purifying waste water from the 
facilities in industrial waste water treatment plants with fur-
ther elimination of trace substances. Here, not only activated 
carbon and ozonation can be used – as it is done in the fourth 
treatment stages of municipal sewage treatment plants. De-
pending on the load situation, e. g. membrane filtration sys-
tems and UV irradiation can be used as well. It might also be 
useful to separately collect waste water from hospitals con-
taminated with specific, poorly degradable substances such 
as e. g. X-ray contrast media.
Apart from the harmful effect of the inputs, the proportio-
nality of tangible measures to reduce pharmaceutical sub-
stances strongly depends on the level of knowledge regard-
ing the unintended side effects of human and veterinary 
medicines as well as on the confidence in this knowledge. 
Besides measures that directly reduce the discharge of phar-
maceutical residues into the environment, improving the 
base of information and closing the gaps of knowledge are 
therefore important elements for better evaluating in the fu-
ture which measures should be taken and how much effort 
should be made to reduce micropollutants. This includes a 
broader monitoring of micropollutants and their environ-
mental impacts, research into the environmental compati-
bility of active pharmaceutical ingredients, but also a sys-
tematic monitoring of side effects in the environment – the 
so-called ecopharmacovigilance (EPV). In particular, it 
would make sense to complement the existing pharmaco-
vigilance system for human medicines – which records the 
or they are washed into surface waters when it rains. The dif-
ferent environmental compartments are interconnected by 
the water cycle.
What can be done concretely?
In accordance with the various sources and entry paths, there 
are basically three areas in which measures to reduce micro-
pollution of groundwater and surface waters by pharmaceu-
tical substances can be applied (fig. 2).
In the health sector, the need 
for medicines could be slightly 
reduced – for example as a side 
effect of general health pro-
motion and preventive meas-
ures – as suggested by a pilot 
study in Baden-Württemberg. 
It is also proposed that the de-
velopment of new medicines 
should not only focus on the 
therapeutic effect, but also 
on minimising undesirable 
environmental impacts. Rais-
ing the awareness of doctors 
and patients with regard to 
the problem of pharmaceuti-
cal residues can also have an 
impact on the consumption 
of medicines. Another area 
is the disposal of old and re-
sidual medicines. Although 
environmentally friendly and 
safe disposal methods already 
exist, they are not sufficiently used – because they are often 
unknown. Wide-ranging information campaigns could help 
to ensure that old and residual medicines are no longer im-
properly disposed of via the sewage system.
With regard to livestock farming, there are also possibilities to 
reduce the consumption of medicines without endangering 
animal welfare. Examples are education and training meas-
ures for farmers and veterinarians on preventive measures to 
improve animal health and thus reduce the consumption of 
medicines. The way in which the so-called farm manure – i. e. 
liquid manure and dung – is stored, processed and spread on 
fields influences the degradation and bioavailability of phar-
maceutical residues. Moreover, buffer strips along waters in 
fields or improved land management of pasture farms could 
reduce the input of farm manure and thus also pharmaceuti-
cal residues into waters.
In the field of water management, the fourth treatment stage 
of municipal sewage treatment plants is certainly the most 
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Fig. 2 Entry paths of pharmaceutical residues in water bodies and potential 
 approaches for countermeasures
Illustration by TAB based on Ebert et al. 2014
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legal regulations and accompanied by appropriate admin-
istrative measures. Moreover, a broad acceptance by and 
active participation of as many stakeholders as possible 
is an important prerequisite for the success of a strategy 
concerning pharmaceutical residues and micropollut-
ants. It addresses companies, associations, health insur-
ance companies, veterinarians, farmers and consumers.
 › Financing: The implementation of a strategy against 
pharmaceutical residues and other micropollutants in 
the water involves significant costs. There are already cost 
estimates as well as tangible financing proposals for the 
important measure of a fourth treatment stage. For many 
of the other measures discussed, however, there are not 
even any rough cost estimates available. In this respect, 
it is currently not possible to provide reasonably reliable 
projections of the total costs regarding the different com-
binations of measures. The example of Switzerland, where 
the fourth treatment stage has recently become mandato-
ry for large plants and polluted waters, shows that costly 
measures can also be financed if there is a political will 
to implement them. For the refinancing of measures, 
e. g. general budgetary resources, fees, an increase or 
improved efficiency of the waste water charge or other 
charges can be considered.
medical side effects at a central point – with a comprehen-
sive environmental information system.
Wanted: a reasonable overall strategy
Increasing consumption of medicines, ever higher concen-
trations of pharmaceutical residues in water as well as more 
and more indications with regard to harmful effects are argu-
ments for not only collecting more intensively and systemati-
cally information on residues and their effects, but also taking 
reduction and prevention measures in due time. A meaning-
ful strategy will certainly consist of a smart combination of 
different measures and should not be reduced to the question 
of the extent to which municipal sewage treatment plants 
should be complemented with a fourth treatment stage. The 
aim must be to reduce the inputs of pharmaceutical residues 
from different sources, but at the same time to improve the 
base of knowledge, strengthen the ›polluter pays‹ principle 
and promote acceptance.
The development of a reasonable overall strategy for dealing 
with pharmaceutical residues in water is essentially a political 
task that must ultimately be tackled within the framework of 
a democratic decision-making process. The following gene-
ral information should be taken into consideration:
 › Integration into a micropollutant strategy: A strategy 
against pharmaceutical residues should be embedded in 
a more comprehensive micropollutant strategy, i. a. be-
cause pharmaceutical residues are only one class among 
many micropollutants and, in particular, because up-
grading municipal sewage treatment plants with a fourth 
treatment stage is an important option that proves to be 
effective against a wide range of micropollutants.
 › Implementation and participation: Besides the EU, the 
German Federal Government sets the essential legal and 
administrative framework conditions, in particular with 
regard to water law and pharmaceutical law. In 2016, the 
Federal Environment Ministry (BMU) for the initiated a 
multi-annual stakeholder dialogue on a »Trace Substance 
Strategy of the Federal Government«. It is to be hoped 
that this dialogue will provide impetus which will be tak-
en up by the various political stakeholders, translated into 
